Free express shipping over $999 · Verified pharmaceuticals · Discreet packaging worldwide
Skip to order
Prescription only medicine

Lanib 250 mg Tablets

Lapatinib 250 mg · Generic equivalent of Tykerb

Lanib 250 mg Tablets is a trusted medication containing Lapatinib, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.

Active ingredient
Lapatinib
Strength
250 mg
Form
Tablet
Made in
India
Prescription
Required
Commonly used forBreast Cancer
$130.00 per pack of 30 tablets

Prescription required — upload it at checkout.

Generic equivalent of Tykerb — up to 80% less than the branded price

Verified pharmacy Genuine medication Tracked shipping Medically reviewed by David Kelly
Licensed Pharmacy Trust & safety
Licensed Manufacturers Every medicine from a licensed manufacturer
Dedicated Oncology Team Doctor + pharmacist review every order before dispatch
Worldwide Delivery UK · US · AU · EU · NZ — tracked and insured
About this medicine

What is Lanib 250 mg Tablets?

Lapatinib is a targeted medicine taken as a tablet for breast cancer that is 'HER2-positive' — meaning the cancer cells carry too much of a growth-signal protein called HER2 — and has spread beyond the breast or come back after other treatment. It is given together with capecitabine (a chemotherapy tablet), or with letrozole for women whose cancer is also hormone-receptor-positive and who have been through the menopause, or with trastuzumab.

Unlike trastuzumab, which is an antibody given by infusion and works on the outside of the cell, lapatinib is a small molecule that gets inside the cell and blocks the HER2 signal there. It can therefore still work after trastuzumab has stopped helping.

It is taken once a day on an empty stomach, and your heart, liver and skin are monitored during treatment. Lapatinib is a prescription-only medicine; a valid prescription must be provided at checkout.

How it works

How does Lapatinib work?

HER2 and EGFR are receptors on the surface of breast cancer cells that, when switched on, send a signal into the cell telling it to grow and divide. In HER2-positive cancer there are far too many HER2 receptors, so the signal is constant. Lapatinib enters the cell and blocks the 'kinase' part of both HER2 and EGFR — the part that actually passes the message on — so the growth signal stops. Because it works inside the cell rather than on the receptor's outer surface, it can be effective in tumours that have become resistant to trastuzumab.

Entering the cell

Lapatinib is a small molecule that crosses the cell membrane and reaches the inner part of the HER2 and EGFR receptors.

Kinase blockade

It binds the ATP pocket of both receptors reversibly, so they cannot phosphorylate and activate the downstream growth pathways (PI3K/AKT and MAPK).

Growth arrest

With the growth signal cut off, HER2-driven cancer cells stop dividing and die; combining with capecitabine or an anti-oestrogen attacks the tumour on a second front.

Uses

What is Lapatinib used for?

HER2-positive advanced or metastatic breast cancer, with capecitabine

After prior treatment including an anthracycline, a taxane and trastuzumab.

FDA EMA CDSCO
HER2-positive, hormone-receptor-positive metastatic breast cancer, with letrozole

Postmenopausal women for whom hormonal therapy is indicated.

FDA EMA
HER2-positive metastatic breast cancer, with trastuzumab

Hormone-receptor-negative disease that has progressed on trastuzumab plus chemotherapy.

EMA

Only your oncologist can determine whether this medicine is right for your diagnosis. The above is for information only.

Dosage

How to take Lanib 250 mg Tablets

Your oncologist will prescribe your exact dose. The right dose for you depends on your weight, kidney and liver function, and — for some medicines — your genetic test results.

Always take exactly as prescribed. Do not change your dose or stop taking this medicine without speaking to your doctor first, even if you feel well.

Missed a dose? Skip a missed dose and take the next one at the usual time. Do not double up.

With food? Take on an empty stomach, at least one hour before or one hour after a meal. Swallow whole with water. Avoid grapefruit and grapefruit juice.

Important safety information

Safety & warnings

Please read this section before taking Lanib 250 mg Tablets and discuss any concerns with your oncologist.

Important: Hepatotoxicity (liver injury)

Lapatinib has caused severe and in some cases fatal liver injury, usually within the first months of treatment. Liver function tests are checked before starting, every four to six weeks during treatment, and whenever symptoms suggest a problem. Report yellowing of the skin or eyes, dark urine, pale stools, loss of appetite or pain under the right ribs immediately; treatment is stopped permanently if severe liver injury occurs.

Common side effects

Side effects affect some people, not everyone. Most are manageable — let your treatment team know about anything that concerns you.

  • Diarrhoea
  • Hand-foot syndrome (redness, soreness of palms and soles)
  • Nausea and vomiting
  • Rash, dry skin, acne-like spots
  • Tiredness (fatigue)
  • Mouth soreness, loss of appetite
  • Nail changes
  • Raised liver enzymes

Contact your doctor immediately if you notice:

  • Yellow skin or eyes, dark urine, pale stools, pain under the right ribs Stop and contact your oncologist immediately — possible liver injury (boxed warning).
  • Diarrhoea that is severe, lasts more than a day, or comes with fever or dehydration Contact your team the same day; anti-diarrhoeals are usually prescribed to keep at home and start at the first loose stool.
  • Breathlessness, swollen ankles, fast heartbeat Seek urgent review — lapatinib can reduce the heart's pumping strength; heart scans are done before and during treatment.
  • New dry cough or breathlessness without other cause Seek prompt review — possible lung inflammation (pneumonitis).
  • Palpitations, fainting Seek urgent care — lapatinib can prolong the QT interval; ECG and electrolytes are monitored.
  • Severe blistering skin reaction Stop and contact your team immediately.

Important: tell your doctor about these medicines

Taking Lapatinib with certain other medicines can be dangerous. Always tell every doctor, dentist, and pharmacist about all medicines you are taking.

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) and grapefruit Major

    Increase lapatinib levels markedly.

  • Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's wort) Major

    Reduce lapatinib levels and may make it less effective.

  • Medicines that prolong the QT interval (some antiarrhythmics, antipsychotics, antibiotics, antiemetics) Major

    Additive risk of dangerous heart rhythms.

Pregnancy & breastfeeding

Lapatinib can harm an unborn baby. It should not be used in pregnancy, and women who could become pregnant should use effective contraception during treatment and for at least one week after the last dose.

Do not breastfeed during treatment or for one week after the last dose.

Effects on human fertility are not established. Discuss fertility preservation before starting if relevant.

Storage

How to store Lanib 250 mg Tablets

Temperature

Store at 20–25°C (68–77°F).

Light & moisture

Keep in the original bottle, tightly closed.

Keep away from children

Keep out of the sight and reach of children.

Safe handling

Anticancer medicine: swallow whole, do not crush; wash hands after handling. Return unused tablets to a pharmacy.

Travelling

Carry in the original bottle with your prescription and an oncologist's letter. Five or six tablets a day adds up — count what you need for the trip plus a few days.

Reviewed for accuracy

Medically reviewed content

David Kelly

David Kelly

B.Pharm

David Kelly is a licensed clinical pharmacist with 13 years of experience. He holds a B.Pharm from Delhi University. At OnlineMeds, he reviews medicine and health content to help ensure it is accurate, evidence-based, and easy to understand.

Our commitment to you

How we support oncology patients

We understand that accessing the right cancer medicine can feel overwhelming. Here is what you can expect from us.

Personal oncology support

Every enquiry is reviewed by our oncology doctor and pharmacist team — not an automated system.

Genuine, verified medicine

Sourced exclusively from licensed pharmaceutical manufacturers. Every batch is traceable from origin to your door.

Prescription checked before dispatch

We verify every prescription with our internal medical team. No shortcuts, no exceptions.

Cold-chain logistics

Temperature-sensitive medicines shipped with appropriate packaging to maintain integrity.

Discreet, plain packaging

No pharmacy branding or product name on the outer packaging.

Up to 80% less than branded

Generic oncology medicines contain the same active ingredient as the originator brand — at a fraction of the cost.

FAQ

Frequently asked questions

Is Lapatinib the same as Tykerb?

Lapatinib is the active ingredient in Tykerb. A generic Lapatinib medicine contains the same active ingredient at the same strength and is taken the same way — the main difference is cost. Always use it as prescribed by a licensed medical professional.

How is Lanib 250 mg Tablets different from Herceptin (trastuzumab)?

Both target HER2. Trastuzumab is an antibody given by infusion that attaches to the outside of the receptor; lapatinib is a tablet that gets inside the cell and blocks the receptor's signalling machinery. Because they act at different points, lapatinib can still work after trastuzumab has stopped, and the two are sometimes used together.

[2] NCI Drug Information: Lapatinib Ditosylate

Why do I take five or six tablets at once?

The tablets are 250 mg each and the usual daily dose is 1,250–1,500 mg. The whole dose is taken at one time, once a day, on an empty stomach — splitting it into smaller doses through the day is not how it was studied and is not recommended.

[1] FDA prescribing information: Tykerb (lapatinib) — DailyMed

Why on an empty stomach?

Food — especially a high-fat meal — increases lapatinib absorption several-fold, which would make side effects unpredictable. Taking it at least an hour away from meals keeps levels consistent with the approved dose.

[1] FDA prescribing information: Tykerb (lapatinib) — DailyMed

What should I do about diarrhoea?

Diarrhoea is the most common side effect, more so with capecitabine. Your oncologist will usually give you loperamide to keep at home with instructions to start it at the first loose stool. Drink plenty of fluids and call your team if it is severe, bloody, or lasts more than a day — the dose can be paused.

[4] MedlinePlus: Lapatinib

How often will my liver and heart be checked?

Liver blood tests before starting and every four to six weeks (lapatinib carries a boxed warning for liver injury); a heart scan (echocardiogram or MUGA) before starting and periodically after, because HER2-targeted drugs can reduce the heart's pumping strength. Both are precautionary and most people have no problems.

[1] FDA prescribing information: Tykerb (lapatinib) — DailyMed

Is Lanib 250 mg Tablets the same as Tykerb?

Lanib 250 mg Tablets contains the same active ingredient, lapatinib, at the same 250 mg strength as the originator brand Tykerb (Tyverb in Europe). Generic medicines must meet the same regulatory standards for quality, safety and effectiveness. Used as prescribed by a licensed medical professional.

[3] EMA: Tyverb — European public assessment report

Can I drink grapefruit juice?

No. Grapefruit and grapefruit juice block the enzyme that clears lapatinib and can push levels up. Other citrus fruits are fine.

[1] FDA prescribing information: Tykerb (lapatinib) — DailyMed

Do I need a prescription to order Lanib 250 mg Tablets?

Yes. Lapatinib is prescription-only. Upload your oncologist's prescription at checkout; our pharmacist team reviews it before dispatch. Used as prescribed by a licensed medical professional.

Sources

References

  1. 1. FDA prescribing information: Tykerb (lapatinib) — DailyMed. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tykerb U.S. National Library of Medicine. Accessed 12 Sep 2026.
  2. 2. NCI Drug Information: Lapatinib Ditosylate. https://www.cancer.gov/about-cancer/treatment/drugs/lapatinibditosylate National Cancer Institute. Accessed 12 Sep 2026.
  3. 3. EMA: Tyverb — European public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb European Medicines Agency. Accessed 12 Sep 2026.
  4. 4. MedlinePlus: Lapatinib. https://medlineplus.gov/druginfo/meds/a607055.html U.S. National Library of Medicine. Accessed 12 Sep 2026.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional — specifically your oncologist — before starting, changing, or stopping any medication. Information is based on NDA #022059, NCI Drug Information, and NHS patient information.
Shopping cart
Shop
0 items Cart
My account